CORRELATION BETWEEN INSULIN RESISTANCE AND SEVERITY OF CORONARY ARTERY DISEASE IN NON-DIABETES

ROHIT SHENOY1, RAJESH BHAT2, MUKUND SRINIVASAN1, CHAKRAPANI MAHABALA1, UNNIKRISHNAN BHASKARAN3

1Department of Medicine, Kasturba Medical College, Manipal University, Mangalore, Karnataka, India. 2Department of Cardiology, Kasturba Medical College, Manipal University, Mangalore, Karnataka, India. 3Department of Community Medicine, Kasturba Medical College, Manipal University, Mangalore, Karnataka, India. Email: drrajeshu@gmail.com

Received: 11 August 2016, Revised and Accepted: 16 August 2016

ABSTRACT

Objective: There is an increased risk of coronary artery disease (CAD) in both diabetes and non-diabetes. Insulin resistance (IR) has been associated with the development of CAD in both these populations. However, there are not many studies on correlation between IR and severity of CAD in non-diabetic individuals. This study aimed to establish a correlation between IR and severity of CAD in non-diabetic individuals.

Methods: A cross-sectional study of 79 consecutive non-diabetic patients undergoing coronary angiogram for evaluation of clinically suspected CAD at a tertiary care hospital in Mangalore, Karnataka, were recruited. Clinical history, anthropometric, and biochemical parameters were analyzed. IR was determined by homeostasis model assessment-IR (HOMA-IR). The severity of CAD was assessed by Modified Gensini score. A Pearson correlation was done to find out the relation between HOMA-IR and Gensini core.

Results: The correlation between log of HOMA-IR and severity of CAD as assessed by Gensini score (r=−0.053 and p=0.64) was not significant in non-diabetic patients. The correlations between severity of CAD and other known risk factors of CAD were also not significant.

Conclusions: HOMA-IR is negatively associated with severity of CAD in non-diabetes.

Keywords: Insulin resistance, Coronary artery disease, Gensini score.

© 2016 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/) DOI: http://dx.doi.org/10.22159/ajpcr.2016.v9i6.14637

INTRODUCTION

The major cause of death worldwide is coronary artery disease (CAD), and more than 60% of the global burden of disease (GBD) occurs in developing countries [1,2]. GBD 2010 study showed that death from CAD increased by 87.8% between 1990 and 2010 in South Asia, and a further rise by 50% is expected by 2030 [3,4].

The Chennai Urban Population Study showed that the total prevalence of CAD was 9.1% among South Indian subjects with normal glucose tolerance [5]. Cardiovascular diseases have a multi-factorial causation, [6] and insulin resistance (IR) is one such non-conventional risk factor that can explain a major part of the pathogenesis of CAD [7].

IR increases the risk of CAD in both diabetic as well as non-diabetic [8] patients. IR has also been identified as a factor in the development of atherosclerosis [9], and hyperinsulinemia has been associated with an increased death in CAD [10]. A significant positive linear correlation between IR and severity of coronary atherosclerosis has been shown in diabetes between the Indian populations [11]. However, there are not many studies in the same population that correlates the IR with the severity of coronary atherosclerosis quantitatively in non-diabetic patients. If we are able to establish a significant association between IR and severity of CAD, it would help us to identify the individuals who are likely to develop severe disease from the beginning itself.

In this study, IR is calculated by homeostasis model assessment-IR (HOMA-IR) [12] and is correlated with the severity of coronary atherosclerosis as assessed by Modified Gensini score following a coronary angiogram [13] in non-diabetic individuals.

METHODS

In this cross-sectional study, 79 consecutive non-diabetic patients who satisfied the diagnostic criteria as recommended by the American Diabetes Association [14] and undergoing coronary angiogram for evaluation of clinically suspected CAD at a tertiary care hospital were recruited. The patients aged between 45 and 65 years were recruited, as studies show that beyond 65 years of age, the extent and degree of CAD remain same in all the population [15]. Patients with Type 2 diabetes mellitus, on steroids, chronic kidney disease, and valvular heart diseases were excluded from the study. The study protocol was approved by the Institutional Ethics Committee. An informed consent was obtained from the study participants.

All the clinical findings were noted. Anthropometric measurements such as height, weight, waist, and hip circumference were noted as per standard norms [16]. Body mass index and waist-hip ratio were calculated. Biochemical parameters such as fasting blood sugar, fasting insulin, fasting lipid profile, glycated hemoglobin, and urine microalbumin were analyzed as previously described by Srinivasan et al. [11]. The degree of IR was measured by HOMA 2 computerized method [12]. In large epidemiological studies, the use of HOMA-IR has been shown to correlate well with the gold standard hyper-insulinemia euglycemic glucose clamp technique for the measurement of IR [17]. To achieve constant phase and to avoid changes in IR that may occur due to the burden of the disease and angiographic procedure, the blood test was done 2 weeks after coronary angiogram [18]. The Modified Gensini scoring method was used to assess the severity of CAD [13]. Gensini scoring was done by a cardiologist, who was blind to other parameters.

Statistical analysis

Data were expressed as mean±standard deviation. The correlation between these parameters was assessed by calculating Pearson’s correlation coefficient. p<0.05 was considered statistically significant. HOMA-IR values were logarithmically transformed for analysis [12]. Data were analyzed using statistical software for the social sciences (SPSS version 15, Chicago, IL, USA).
RESULTS

The characteristics of the study population are shown in Table 1.

The mean age of the subjects was 57.36±8.08. The majority of the study population was males 64 (81%) and females 15 (19%). At the time of the study, 29 (37%) of the patients had been diagnosed with hypertension and were on antihypertensive treatment. The overall Gensini score ranged from 3 to 14 among non-diabetics.

The scatterplot representing the relation between Gensini score and IR in non-diabetic patients is shown in Fig. 1.

The correlation between log of HOMA-IR and severity of CAD as assessed by Gensini score (r=−0.053 and p=0.64) was not significant in non-diabetic patients.

The correlations between severity of CAD and other known risk factors of CAD were also not significant in non-diabetic patients (Table 2).

DISCUSSION

We have demonstrated the correlation between IR (HOMA-IR) and angiographic severity of CAD in 79 consecutive non-diabetic patients who underwent angiogram for the screening of clinically suspected CAD.

Our study showed that the severity of CAD is not associated with IR in the non-diabetic population, which is similar to a study by Kruszelnicka et al. where no correlation was seen between the IR as measured by HOMA and Gensini score in 151 non-diabetic men [19].

Similarly, Vonbank et al. [20] reported no difference in HOMA-IR among 996 patients who underwent coronary angiography with varying severity of disease, irrespective of diabetes status and a study in 797 men by Solymoss et al. [21] found no association between the number of coronary arteries with >50% stenosis and fasting insulinemia, a surrogate marker for IR.

However, studies in smaller groups (n=38-83) found a positive relationship between angiographic CAD extent and IR as assessed by insulin suppression test or HOMA-IR [22-24].

Large data also suggest that IR has a pivotal role in atherosclerosis [25]. IR is closely related with an increased risk of cardiovascular disease [26]. The endothelial dysfunction which develops due to altered insulin signaling in the endothelial cells has resulted in the increased susceptibility to cardiovascular disease [26].

The third U.S. National Health and Nutrition Examination Survey III during a mean follow-up of 8.5 years found that there was independent association of HOMA-IR and mortality from cardiovascular events in non-diabetic adults [27]. Similar results were also obtained by a meta-analysis, which concluded that there 46% increase in the relative risk of symptomatic CAD per 1-SD increment in HOMA-IR [28].

In a cross-sectional study, a significant positive linear correlation between IR and severity of coronary atherosclerosis has been shown in diabetics vs the Indian populations. In individuals with Type 2 diabetes mellitus, the evolution of insulin resistance is unique.

It precedes the onset of diabetes and remains fairly constant throughout the disease in spite of controlling for controlling for conventional risk factors [29]. In the UK prospective diabetes study, the IR as measured by HOMA-IR method has been shown to be relatively stable during the many years of treatment even after with the conventional treatment of Type 2 diabetes mellitus, [30,31].

However, in non-diabetics, IR seems to be fluctuating, and that is why we were not able to appreciate the correlation with severity of CAD.

Therefore, it is hypothesized that the morbidity is associated with elevated levels of HOMA-IR in non-diabetic CAD patients but not the severity.

Since major therapeutic decision depends on the severity of CAD, it is important to identify the factor responsible for severe CAD in non-diabetic individuals. But in this study, IR and other conventional risk factors of CAD were not associated with severity of CAD in non-diabetic patients. Thus, further prospective studies are needed to find out which of these risk factors is contributing to the severity of CAD in non-diabetic individuals.
LIMITATIONS

This study has several limitations, as this study included only patients with proven CAD, there is no control group. The study population and size were limited. The cross-sectional design and a single center study.

CONCLUSIONS

The findings of the study indicate that though HOMA-IR is not associated with severity of the disease in the non-diabetic population, and hence the role of insulin resistance leading to severe CAD would be limited in non-diabetes. More research is needed to study how IR influences coronary atherosclerosis in non-diabetics.

REFERENCES

1. WHO. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2008b.
2. WHO. World Health Statistics 2009. Geneva: World Health Organization; 2009e.
3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380(9859):2095-128.
4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3(11):e442.
5. Mohan V, Deepa R, Rani SS, Premalatha G. Prevalence of coronary artery disease and its relationship to lipids in a selected population in South India: The Chennai Urban Population Study (CUPS No. 5). J Am Coll Cardiol 2001;38(3):682-7.
6. Yusuf S, Reddy S, Oumpus S, Andan S. Global burden of cardiovascular diseases: Part I: General considerations, the epidemiologic transition, risk factors, and impact of urbanization. Circulation 2001;104(22):2746-53.
7. Reaven GM. A syndrome of resistance to insulin stimulated uptake (syndrome X). Definitions and implications. Cardiovasc Risk Factors 1993;3:2-11.
8. Bonora E, Kiechl S, Temporin CA, Schwinger J, Egger G, Meigs JB, et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population. The Bruneck study. Diabetes Care 2007;30(2):318-24.
9. Kim J, Chae YK, Chernoff A. The risk for coronary heart disease according to insulin resistance with and without Type 2 diabetes. J South India: The Chennai Urban Population Study (CUPS No. 5). J Am Coll Cardiol 2001;38(3):682-7.
10. Després JP, Lamarche B, Maurôte P, Cantin B, Dagenais GR, Moorjani S, et al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996;334(15):952-7.
11. Srinivasan MP, Kamath M, Unnikrishnan B, Ullal A, Kotekar MF, et al. Correlation of severity of coronary artery disease with insulin resistance. N Am J Med Sci 2013;5(10):611-4.
12. Wallace TM, Levy JC, Matthews DR. Use and abuse of HOMA modeling. Diabetes Care 2004;27(6):1487-95.
13. Kim JY, Mun HS, Lee BK, Yoon SB, Choi KY, Shin JY, et al. Impact of metabolic syndrome and its individual components on the presence and severity of angio graphic coronary artery disease. Yonsei Med J 2010;51(5):676-82.
14. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2010;33 Suppl 1:S62-9.
15. Natale A, Vichi S, Landi P, Severi S, L‘Abate A, Ferrannini E. Coronary atherosclerosis in Type II diabetes: Angiographic findings and clinical outcome. Diabetologia 2000;43(5):632-41.
16. Vishnupriya, R, Ezhilramya J, Meenakshi B. Metformin in the prevention of metabolic syndrome associated with initiation of atypical antipsychotic therapy in adolescents and young adults - A randomized, open labelled, single centered study. Int J Pharm Pharm Sci 2016;8(4):200-6.
17. Katsuki A, Sumida Y, Gabaazza EC, Murashima S, Furuta M, Araki-Sasaki R, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with Type 2 diabetes. Diabetes Care 2001;24(2):362-5.
18. Kwon K, Choi D, Koo BK, Ryu SK. Decreased insulin sensitivity is associated with the extent of coronary artery disease in patients with angina. Diabetes Obes Metab 2005;7(5):579-85.
19. Kruzelniecka O, Surdacki A, Golay A. Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethyl arginine but not insulin resistance in non-diabetic men with stable angina: A cross-sectional study. Cardiovasc Diabetol 2013;12:145.
20. Vonbank A, Saely CH, Reim P, Beer S, Breu lij S, et al. Insulin resistance is associated with the metabolic syndrome and is not directly linked to coronary artery disease. Clin Chim Acta 2007;412(11-12):1003-7.
21. Solyomoss BC, Marcil M, Chaour M, Gillix BM, Postras AM, Campeau L. Fasting hyperinsulinism, insulin resistance syndrome, and coronary artery disease in men and women. Ann J Cardiol 1995;76(16):1152-6.
22. Takezako T, Sakai K, Zhang B, Shirai K, Arakawa K. Insulin resistance and angiographical characteristics of coronary atherosclerosis. Jpn Circ J 1999;63(9):666-73.
23. Shinozaki K, Suzuki M, Ikebuchi M, Hara Y, Harano Y. Demonstration of insulin resistance in coronary artery disease documented with angiography. Diabetes Care 1996;19(1):1-7.
24. Granér M, Syvänen A, Kahrilä J, Nieminen MS, Taskinen MR. Insulin resistance as predictor of the angiographic severity and extent of coronary artery disease. Ann Med 2007;39(2):137-44.
25. Zornitzki T, Ayzenberg O, Gandelman G, Vered S, Vaskil E, Faraggi D, et al. Diabetes, but not the metabolic syndrome, predicts the severity and extent of coronary artery disease in women. QJM 2007;100(9):575-81.
26. Aziz A, Wheatcroft S. Insulin resistance in Type 2 diabetes and obesity: Implications for endothelial function. Expert Rev Cardiovasc Ther 2011;9(4):403-7.
27. Ausk KJ, Broyko EJ, Joannou GN. Insulin resistance predicts mortality in nondiabetic individuals in the U.S. Diabetes Care 2010;33(6):1179-85.
28. Gast KB, Tjerdema N, Stijnen T, Smit JW, Dekkers OM. Insulin resistance and risk of incident cardiovascular events in adults without diabetes: Meta-analysis. PLoS One 2012;7(12):e52036.
29. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: Therapeutic potential, patient selection and clinical use. Am J Med 2009;122 6 Suppl: S37-50.
30. Matthews DR, Cull CA, Stratton IM, Holman RR, Turner RC. UKPDS 36: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group. Diabet Med 1998;15(4):297-303.
31. Kahn SE. The relative contribution of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes. Diabetologia 2003;46(1):3-19.